![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
A REVIEW ON LOBEGLITAZONE AND ITS THERAPEUTIC BENEFITS
Avi Shah*, Pavan Patel, Faizan Khoraziya, Jignesh Parmar, Dr. Khushbu Patel and Dr. C. N. Patel
ABSTRACT
Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and β-cell dysfunction. Among available oral antidiabetic agents, only the Thiazolidinediones (TZDs) primarily target insulin resistance. Thiazolidinediones improve insulin sensitivity by activating per-oxisome proliferator-activated receptor γ. Lobeglitazone is a newer oral hypoglycemic agent that has been tested in Type 2 diabetes mellitus (T2DM). We aim to conduct a narrative review to find out the therapeutic benefits of Lobeglitazone in patients with Type 2 diabetes mellitus. We retrieved all available results of phase 1 to phase 3 studies of Lobeglitazone in Type 2 diabetes mellitus. Subsequently, we reviewed the results narratively. Lobeglitazone exhibits as much antidiabetic activity as other Thiazolidinediones such as Pioglitazone and Rosiglitazone. Side effects of Lobeglitazone included peripheral Keywords: Type 2 diabetes mellitus (T2DM), Thiazolidinediones (TZDs), Lobeglitazone. [Download Article] [Download Certifiate] |